Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 UCAR-T Cells in Autoimmune Diseases
NCT07212322Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CD19 UCAR-T cells in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and 4 more, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose Limiting Toxicity and Frequency of Adverse Events and Serious Adverse Events at 12 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
CD19 UCAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)Sjögren's syndromeantiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT07212322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212322.